A lot has happened in the field of lung cancer screening in recent months. The ongoing discussion and documentation published by the scientific community and policymakers are of great importance to the entire European community and perhaps beyond. Lung cancer is the main worldwide killer. Low-dose computed tomography-based screening, together with smoking cessation, is the only tool to fight lung cancer, as it has already been proven in the United States of America but also European randomized controlled trials. Screening requires a lot of well-organized specialized work, but it can be supported by artificial intelligence (AI). Here we discuss whether and how to use AI for patients, radiologists, pulmonologists, thoracic surgeons, and all hospital staff supporting screening process benefits.
Keyphrases
- artificial intelligence
- machine learning
- smoking cessation
- big data
- low dose
- deep learning
- computed tomography
- healthcare
- randomized controlled trial
- end stage renal disease
- mental health
- chronic kidney disease
- magnetic resonance imaging
- ejection fraction
- emergency department
- replacement therapy
- palliative care
- high dose
- prognostic factors
- systematic review
- magnetic resonance
- spinal cord injury
- acute care
- drug induced
- advance care planning